{"id":41055,"date":"2026-10-06T04:34:51","date_gmt":"2026-10-06T04:34:51","guid":{"rendered":"https:\/\/digify.com\/?p=41055"},"modified":"2026-10-06T04:58:53","modified_gmt":"2026-10-06T04:58:53","slug":"biotech-data-room-managing-sensitive-information","status":"publish","type":"post","link":"https:\/\/digify.com\/de\/blog\/biotech-data-room-managing-sensitive-information\/","title":{"rendered":"From Pitch Deck to Due Diligence: Managing Sensitive Information in a Biotech Fundraise"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

TL;DR<\/h2>\n
\n

Biotech fundraises start with a pitch deck, but diligence can extend into IP, financial, technical and regulatory information. For each sensitive document, decide who gets access, what they can do with it, how long access lasts, and what visibility you need afterward. Access isn't static \u2014 it can expand or tighten as investors move through diligence. A biotech data room like Digify supports granular permissions, print and download controls, dynamic watermarking, access expiry and activity logs to manage that process.<\/p>\n<\/div>\n\n\n

A biotech fundraise can start with a pitch deck and high-level company information shared over email. As investor conversations progress, however, diligence may extend into intellectual property, financial information, technical research, regulatory materials and other confidential information \u2014 the point at which many companies start looking at a biotech data room<\/strong> instead of ad hoc file sharing.<\/p>\n\n

That creates a different problem from simply sending investors more files.<\/p>\n\n

The company and its advisors still need to decide what information is appropriate to disclose and when<\/strong>. But once that decision has been made, another set of questions emerges: Who should have access? What should recipients be allowed to do with the information? How long should that access remain available? And what visibility should the company retain after sharing?<\/p>\n\n

Those are information-management decisions, and they become increasingly important as diligence gets deeper.<\/p>\n\n

How should biotech companies manage sensitive information during investor due diligence?<\/h2>\n\n

There is no universal rule for which documents a biotech company should disclose to investors or at what point in a fundraise. Once the company and its advisors decide that sensitive information should be shared, however, the process should make it clear who can access it, what they can do with it, how long that access remains available and what happens after it is shared<\/strong>.<\/p>\n\n

A useful way to think about this is through four questions:<\/p>\n\n

\n \n \n \n \n \n \n \n \n
Question<\/th>\n What you are deciding<\/th>\n <\/tr>\n <\/thead>\n
Who gets access?<\/td>\n Which investors, advisors or diligence participants need the information<\/td>\n <\/tr>\n
What can they do with it?<\/td>\n Whether they can only view it, or also print or download it<\/td>\n <\/tr>\n
How long should access last?<\/td>\n Whether access should remain open indefinitely, expire or be revoked<\/td>\n <\/tr>\n
What happens after sharing?<\/td>\n What activity your team needs visibility into<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n
\n \"The\n
Figure 1. The Controlled Disclosure Framework \u2014 four questions to answer for every sensitive document.<\/figcaption>\n<\/figure>\n\n

This framework does not determine what your company should disclose. Instead, it helps you manage the information after the disclosure decision has been made<\/strong>.<\/p>\n\n

Why biotech diligence can create a different information-sharing problem<\/h2>\n\n

Investor due diligence is not limited to financial statements and corporate records.<\/p>\n\n\n

The World Intellectual Property Organization (WIPO) describes IP due diligence as an audit of a company's intangible assets \u2014 including patents, trade secrets and other intellectual property \u2014 that may be conducted by potential investors, partners or buyers when a venture is raising capital. WIPO notes that trade secrets can cover technical information such as manufacturing processes and pharmaceutical test data, provided the information meets the relevant requirements for trade-secret protection.<\/p>\n\n

The implication is not that every biotech company must place the same scientific or IP documents into its investor data room.<\/p>\n\n

It is that a pitch deck, a financial forecast and confidential technical information may carry very different levels of sensitivity. Treating all three with exactly the same sharing settings may therefore make little sense. For a wider look at the pressures shaping this sector, see our guide to biotech fundraising trends, challenges and data security<\/a>.<\/p>\n\n

The right disclosure strategy will depend on your company. The information controls around that strategy<\/strong> should be just as deliberate.<\/p>\n\n

Think about sensitivity, not only folders<\/h2>\n\n

Data-room advice often starts with folder structures: Corporate, Financial, IP, Regulatory, Clinical, Commercial.<\/p>\n\n

That can be useful for organization, but folders alone do not tell you how information should be handled.<\/p>\n\n

Consider two files in the same folder. One might already contain information that has been widely circulated to prospective investors. Another might contain highly confidential technical details that the company only intends to share with a small group conducting deeper diligence.<\/p>\n\n

Their location might be similar. Their sensitivity might not be.<\/p>\n\n

A better starting point is to ask how sensitive the information is in your specific context<\/strong>.<\/p>\n\n

\n \n \n \n \n \n \n \n \n \n
Information type<\/th>\n Potential sensitivity<\/th>\n Information-management question<\/th>\n <\/tr>\n <\/thead>\n
Public or widely shared company information<\/td>\n Lower<\/td>\n Does this need additional restriction at all?<\/td>\n <\/tr>\n
Fundraising material<\/td>\n Moderate<\/td>\n Who should receive it and for how long?<\/td>\n <\/tr>\n
Financial information<\/td>\n Higher<\/td>\n Does the recipient need a downloadable copy?<\/td>\n <\/tr>\n
IP-related information<\/td>\n Potentially high<\/td>\n Should access be limited to specific recipients?<\/td>\n <\/tr>\n
Confidential scientific or technical information<\/td>\n Potentially high<\/td>\n What level of access is appropriate for this recipient?<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n

These categories are illustrative, not disclosure recommendations. The sensitivity of any particular document and its appropriate treatment should be determined by the company with the relevant internal and professional advisors.<\/p>\n\n\n

The broader information-security principle is well established. NIST's guidance on information exchanges says information shared between organizations should receive protection commensurate with its risk before, during and after the exchange.<\/p>\n\n

\n

The sharing method should reflect the sensitivity of what is being shared.<\/p>\n<\/div>\n\n

Access can change as diligence progresses<\/h2>\n\n

Investor diligence is not one event.<\/p>\n\n

A company might initially have conversations with a broad group of prospective investors, then move into more detailed discussions with a smaller set of parties. Specialist advisors or technical diligence participants may become involved. Some investors may leave the process while others request additional information.<\/p>\n\n

That means access does not necessarily need to remain static.<\/p>\n\n\n

WIPO's 2026 guidance on using virtual data rooms for IP investment specifically recommends need-to-know permissions, expiring invitations, watermarking, and logging downloads and interactions when managing confidential IP information in a VDR.<\/p>\n\n

\n \n \n \n \n \n \n \n \n
Stage<\/th>\n What typically happens<\/th>\n <\/tr>\n <\/thead>\n
1. Initial evaluation<\/td>\n A recipient receives the information the company has approved for that stage.<\/td>\n <\/tr>\n
2. Qualified interest<\/td>\n The company may decide to provide access to additional information.<\/td>\n <\/tr>\n
3. Detailed diligence<\/td>\n Additional participants or specialists may be given access where appropriate.<\/td>\n <\/tr>\n
4. Process ends<\/td>\n Access can be removed or allowed to expire when it is no longer required.<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n
\n \"The\n
Figure 2. The Diligence Access Ladder \u2014 access expands, changes and eventually expires.<\/figcaption>\n<\/figure>\n\n

The useful capability here is not predicting which scientific document belongs at which stage. It is being able to change access without rebuilding the entire sharing process<\/strong>.<\/p>\n\n

Decision 1: Who actually needs access?<\/h2>\n\n

Once information has been approved for sharing, the next question is who needs to see it.<\/p>\n\n

Different investors may be at different stages of the process. A prospective investor evaluating the opportunity may not need the same access as a lead investor engaged in detailed diligence. External advisors or specialists may need access to a specific subset of information rather than the whole room.<\/p>\n\n

If your diligence process requires those distinctions, your data room should support them. Digify virtual data rooms support data-room, group and granular permissions<\/a>, allowing owners to control access for different recipients rather than applying a single permission model to everyone.<\/p>\n\n

The principle is simple:<\/p>\n\n

\n

Access should follow the disclosure decision, not the other way around.<\/p>\n<\/div>\n\n

Decide who should receive the information first. Then configure the room accordingly.<\/p>\n\n

Decision 2: Does the recipient need a downloadable copy?<\/h2>\n\n

There is an important difference between allowing someone to see<\/strong> a document and allowing them to take a copy away<\/strong>.<\/p>\n\n

For ordinary collaboration, downloading a file may be expected. For more sensitive external sharing, the decision deserves more thought. Ask:<\/p>\n\n